Catalyst Pharms

CPRX NASDAQ
4.390
+0.340
+8.40%
After Hours: 4.490 +0.1 +2.28% 19:39 07/22 EDT
Open
4.060
Prev Close
4.050
High
4.450
Low
4.010
Volume
1.60M
Avg Vol (3M)
2.35M
52 Week High
6.16
52 Week Low
1.850
% Turnover
1.56%
Market Cap
451.53M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Catalyst Pharms CPRX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
MORE >

Recently

Name
Price
%Change